NASDAQ:NVAXNovavax Stock Price, Forecast & News

Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVAX shares have increased by 797.8% and is now trading at $94.36. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novavax.

Novavax is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Novavax.

Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.58) EPS for the quarter, topping the Zacks' consensus estimate of ($0.67) by $0.09. The biopharmaceutical company had revenue of $3.38 million for the quarter, compared to analysts' expectations of $3.50 million. During the same quarter in the prior year, the firm earned ($2.20) EPS. View Novavax's earnings history.

Novavax shares reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

7 Wall Street analysts have issued 1 year price targets for Novavax's shares. Their forecasts range from $15.00 to $148.00. On average, they expect Novavax's stock price to reach $79.93 in the next twelve months. This suggests that the stock has a possible downside of 15.3%. View analysts' price targets for Novavax.

News articles about NVAX stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novavax earned a daily sentiment score of -1.8 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Novavax.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Egalet (EGLT), EXACT Sciences (EXAS), Palo Alto Networks (PANW), Akebia Therapeutics (AKBA), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Cara Therapeutics (CARA), NVIDIA (NVDA) and AT&T (T).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVAX stock can currently be purchased for approximately $94.36.

Novavax has a market capitalization of $5.47 billion and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Novavax employs 373 workers across the globe.

The official website for Novavax is www.novavax.com.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]